Spitalul Clinic De Boli Infectioase Cluj-Napoca
- Address
- Strada Moldovan Iuliu 23, 400348 Cluj Napoca, Romania
Spitalul Clinic De Boli Infectioase Cluj-Napoca
Spitalul Clinic De Boli Infectioase Cluj-Napoca is a specialized infectious disease clinical research center with comprehensive expertise in investigating novel therapeutic interventions for a wide spectrum of infectious diseases. The center demonstrates particular proficiency in conducting complex clinical trials involving both emerging and established pathogens, with a strong focus on viral infections, fungal infections, and bacterial pathogens.
- Viral infections including HIV-1, chronic hepatitis B, and severe acute respiratory viral infections
- Invasive fungal infections and candidemia with innovative adjunctive immunotherapy approaches
- Healthcare-associated bacterial infections including Clostridioides difficile infection and microbiome restoration therapies
- Novel antiviral therapies and long-acting treatment regimens for chronic viral conditions
The center's research portfolio encompasses both Phase 2 and Phase 3 clinical trials, evaluating cutting-edge therapeutic modalities including immunomodulatory agents, antisense oligonucleotides, microbiome-based interventions, and monoclonal antibody therapies. With expertise in managing critically ill patients requiring advanced supportive care, the facility is well-positioned to assess interventions aimed at preventing progression to invasive mechanical ventilation and achieving functional cures in chronic infectious diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Clinic De Boli Infectioase Cluj-Napoca
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Molnupiravir in Non-Hospitalized Adults with SARS-CoV-2 Infection at High Risk for Disease Progression | Merck Sharp & Dohme LLC | Phase III | Recruiting | Feb 2025 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live | 1 | Unknown | 2024-10-31 | 2024-10-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.